Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04557462




Registration number
NCT04557462
Ethics application status
Date submitted
15/09/2020
Date registered
21/09/2020
Date last updated
15/04/2024

Titles & IDs
Public title
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Scientific title
A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan in Adult Participants With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301
Secondary ID [1] 0 0
2020-002200-40
Secondary ID [2] 0 0
CLNP023A2002B
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Primary IgA Nephropathy 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - LNP023

Experimental: LNP023 - All participants are receiving 200 mg b.i.d


Treatment: Drugs: LNP023
Capsule 200 mg (b.i.d.) taken orally twice a day
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number and percentage of participants with serious adverse event
Timepoint [1] 0 0
Date of first administration of (Day 1) to 7 days after the date of the last actual administration of study treatment
Primary outcome [2] 0 0
Number and percentage of participants with adverse event
Timepoint [2] 0 0
Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
Primary outcome [3] 0 0
Number and percentage of participants with adverse events of special interest
Timepoint [3] 0 0
Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual adminstration of study treatment
Primary outcome [4] 0 0
Number and percentage of participants with abnormalities in vital signs
Timepoint [4] 0 0
Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
Primary outcome [5] 0 0
Number and percentage of participants with abnormalities in ECG
Timepoint [5] 0 0
Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
Primary outcome [6] 0 0
Number and percentage of participants with abnormalities in clinical laboratory evaluations
Timepoint [6] 0 0
Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
Secondary outcome [1] 0 0
Annualized total eGFR slope
Timepoint [1] 0 0
Screening visit, Months 1, 3, 6, 9, 12 and every 6 months thereafter
Secondary outcome [2] 0 0
Change from baseline in eGFR
Timepoint [2] 0 0
Screening visit, Months 1, 3, 6, 9, 12 and every 6 months thereafter
Secondary outcome [3] 0 0
Log transformed ratio to baseline in UPCR, UACR
Timepoint [3] 0 0
Screening visit, Months 1, 3, 6, 9, 12 and every 6 months thereafter

Eligibility
Key inclusion criteria
- For LNP023X2203, participants must have completed part 1 or part 2 of the trial. For
LNP023A2301, participants must have completed the entire core trial defined as the
full 24 month treatment period.

- eGFR* = 20 ml/min/1.73m2

*eGFR calculated using the CKD-EPI formula (or modified MDRD formula according to
specific ethnic groups and local practice guidelines)

- Per investigator's clinical judgement, the participant may benefit from receiving the
open-label treatment of iptacopan 200 mg b.i.d.

- Prior Vaccination against Neisseria meningitidis, Streptococcus pneumoniae and
Haemophilus influenzae infections should be up to date (i.e. any boosters required
administered according to local regulations.

- All participants must be on supportive care regimen of ACEi or ARB* as per KDIGO
guidelines.

- participants who are not taking KDIGO guideline doses because they have
documented allergies or intolerance to ACEi and ARB are eligible for the study
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- participants who screen or baseline failed in the CLNP023X2203 Part 1 or Part 2, or
CLNP023A2301 studies or who prematurely withdrew from either study for any reason.

- Evidence of severe urinary obstruction or difficulty in voiding; any urinary tract
disorder other than IgAN at screening and before dosing with LNP023.

- Current (within 4 weeks of study drug administration in the REP) acute kidney injury
(AKI)

- Presence of Rapidly Progressive Glomerulonephritis (RPGN) as defined by 50% decline in
eGFR within the last 3 months.

- Participants treated with immunosuppressive or other immunmodulatory agents such as
but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab,
mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus,
sirolimus, everolimus and/or systemic corticosteroids exposure (>7.5 mg/d
prednisone/prednisolone equivalent) within 5 half-lives of respective medication or 90
days prior to first study drug administration, whichever is shorter. Rituximab
requires 180 days wash out.

- Use of other investigational drugs at the time of enrolment, or within 5 half-lives of
enrolment or within 30 days whichever is longer.

- History of recurrent invasive infections caused by encapsulated organisms, such as
meningococcus and pneumococcus.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/09/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/05/2032
Actual
Sample size
Target
500
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Adelaide
Recruitment hospital [2] 0 0
Novartis Investigative Site - Parkville
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
3065 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Delaware
Country [4] 0 0
United States of America
State/province [4] 0 0
Missouri
Country [5] 0 0
United States of America
State/province [5] 0 0
Nevada
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
Argentina
State/province [7] 0 0
Cordoba
Country [8] 0 0
Argentina
State/province [8] 0 0
Santa Fe
Country [9] 0 0
Belgium
State/province [9] 0 0
Antwerpen
Country [10] 0 0
Belgium
State/province [10] 0 0
Leuven
Country [11] 0 0
Belgium
State/province [11] 0 0
Roeselare
Country [12] 0 0
Brazil
State/province [12] 0 0
PR
Country [13] 0 0
Brazil
State/province [13] 0 0
RS
Country [14] 0 0
Brazil
State/province [14] 0 0
SP
Country [15] 0 0
Canada
State/province [15] 0 0
Ontario
Country [16] 0 0
China
State/province [16] 0 0
Guangdong
Country [17] 0 0
China
State/province [17] 0 0
Ningxia
Country [18] 0 0
China
State/province [18] 0 0
Beijing
Country [19] 0 0
China
State/province [19] 0 0
Qingdao
Country [20] 0 0
China
State/province [20] 0 0
Shanghai
Country [21] 0 0
China
State/province [21] 0 0
Shanxi
Country [22] 0 0
Czechia
State/province [22] 0 0
Praha
Country [23] 0 0
Denmark
State/province [23] 0 0
Aalborg
Country [24] 0 0
Denmark
State/province [24] 0 0
Arhus N
Country [25] 0 0
Denmark
State/province [25] 0 0
Copenhagen
Country [26] 0 0
France
State/province [26] 0 0
Paris
Country [27] 0 0
Germany
State/province [27] 0 0
Berlin
Country [28] 0 0
Germany
State/province [28] 0 0
Freiburg
Country [29] 0 0
Germany
State/province [29] 0 0
Heidelberg
Country [30] 0 0
Germany
State/province [30] 0 0
Magdeburg
Country [31] 0 0
Germany
State/province [31] 0 0
Mainz
Country [32] 0 0
Hong Kong
State/province [32] 0 0
Hong Kong SAR
Country [33] 0 0
India
State/province [33] 0 0
Karnataka
Country [34] 0 0
India
State/province [34] 0 0
New Delhi
Country [35] 0 0
Israel
State/province [35] 0 0
Ashkelon
Country [36] 0 0
Israel
State/province [36] 0 0
Jerusalem
Country [37] 0 0
Israel
State/province [37] 0 0
Petach Tikva
Country [38] 0 0
Italy
State/province [38] 0 0
Napoli
Country [39] 0 0
Japan
State/province [39] 0 0
Aichi
Country [40] 0 0
Japan
State/province [40] 0 0
Hokkaido
Country [41] 0 0
Japan
State/province [41] 0 0
Kanagawa
Country [42] 0 0
Japan
State/province [42] 0 0
Miyagi
Country [43] 0 0
Japan
State/province [43] 0 0
Nagano
Country [44] 0 0
Japan
State/province [44] 0 0
Okayama
Country [45] 0 0
Japan
State/province [45] 0 0
Osaka
Country [46] 0 0
Japan
State/province [46] 0 0
Shiga
Country [47] 0 0
Japan
State/province [47] 0 0
Kyoto
Country [48] 0 0
Korea, Republic of
State/province [48] 0 0
Chungcheongbuk Do
Country [49] 0 0
Korea, Republic of
State/province [49] 0 0
Korea
Country [50] 0 0
Korea, Republic of
State/province [50] 0 0
Seocho Gu
Country [51] 0 0
Korea, Republic of
State/province [51] 0 0
Seoul
Country [52] 0 0
Korea, Republic of
State/province [52] 0 0
Taegu
Country [53] 0 0
Malaysia
State/province [53] 0 0
Kuala Lumpur
Country [54] 0 0
Netherlands
State/province [54] 0 0
Groningen
Country [55] 0 0
Norway
State/province [55] 0 0
Oslo
Country [56] 0 0
Norway
State/province [56] 0 0
Bergen
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Rostov On Don
Country [58] 0 0
Russian Federation
State/province [58] 0 0
St. Petersburg
Country [59] 0 0
Singapore
State/province [59] 0 0
Singapore
Country [60] 0 0
Taiwan
State/province [60] 0 0
Kaohsiung
Country [61] 0 0
Taiwan
State/province [61] 0 0
Taichung
Country [62] 0 0
Taiwan
State/province [62] 0 0
Taipei
Country [63] 0 0
Taiwan
State/province [63] 0 0
Taoyuan
Country [64] 0 0
Thailand
State/province [64] 0 0
Bangkok
Country [65] 0 0
Turkey
State/province [65] 0 0
TUR
Country [66] 0 0
Turkey
State/province [66] 0 0
Kocaeli
Country [67] 0 0
Turkey
State/province [67] 0 0
Talas / Kayseri
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Cambrigdeshire
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Manchester
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Leicester
Country [71] 0 0
United Kingdom
State/province [71] 0 0
London
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Newcastle Upon Tyne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the long-term safety and tolerability, of open label
iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203
or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to
provide study participants the opportunity to receive treatment with iptacopan until
marketing authorizations are received and the drug product becomes commercially available
while enabling collection of long-term safety and tolerability data for the investigational
drug. Furthermore efficacy assessments conducted every 6 months will afford the opportunity
to evaluate the clinical effects of iptacopan on long-term disease progression.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04557462
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
1-888-669-6682
Fax 0 0
Email 0 0
novartis.email@novartis.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04557462